Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS‐CoV‐2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023
Bivalent vaccines protected against symptomatic infection. However, effectiveness waned over time, emphasizing the need to stay up to date with COVID-19 vaccination.
Authors
- Allison Avrich Ciesla (ORCID: https://orcid.org/0000-0001-8739-1005)
- Ruth Link‐Gelles (ORCID: https://orcid.org/0000-0002-9617-806X)
- Ryan E. Wiegand (ORCID: https://orcid.org/0000-0002-9486-1850)
- Amadea Britton (ORCID: https://orcid.org/0000-0003-2684-8846)
- Zachary Smith (ORCID: https://orcid.org/0000-0001-8221-1108)
- Josephine Mak (ORCID: https://orcid.org/0000-0002-2740-0763)
- Katherine E. Fleming‐Dutra (ORCID: https://orcid.org/0000-0002-9215-8811)
- Lauren E. Roper
- Joseph D. Miller
Institutions
- Centers for Disease Control and Prevention (US)
- National Center for Immunization and Respiratory Diseases (US)
- United States Public Health Service (US)
Publication Details
- Journal
- Influenza and Other Respiratory Viruses
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1111/irv.70038
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- U.S. Department of Health and Human Services
- Centers for Disease Control and Prevention
- Office of the National Coordinator for Health Information Technology